The stock of Vaxcyte Inc (PCVX) has seen a -6.30% decrease in the past week, with a -7.62% drop in the past month, and a 33.81% flourish in the past quarter. The volatility ratio for the week is 3.73%, and the volatility levels for the past 30 days are at 2.86% for PCVX.. The simple moving average for the past 20 days is -6.43% for PCVX’s stock, with a 31.14% simple moving average for the past 200 days.
Is It Worth Investing in Vaxcyte Inc (NASDAQ: PCVX) Right Now?
Company’s 36-month beta value is 0.99.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PCVX is 117.31M, and currently, short sellers hold a 7.97% ratio of that floaft. The average trading volume of PCVX on October 30, 2024 was 916.67K shares.
PCVX) stock’s latest price update
The stock price of Vaxcyte Inc (NASDAQ: PCVX) has dropped by -6.42 compared to previous close of 112.80. Despite this, the company has seen a fall of -6.30% in its stock price over the last five trading days. globenewswire.com reported 2024-09-11 that SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, at 10:20 a.m. ET / 7:20 a.m. PT.
Analysts’ Opinion of PCVX
Many brokerage firms have already submitted their reports for PCVX stocks, with Mizuho repeating the rating for PCVX by listing it as a “Buy.” The predicted price for PCVX in the upcoming period, according to Mizuho is $69 based on the research report published on December 07, 2023 of the previous year 2023.
Needham gave a rating of “Buy” to PCVX, setting the target price at $58 in the report published on January 03rd of the previous year.
PCVX Trading at -1.58% from the 50-Day Moving Average
After a stumble in the market that brought PCVX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.80% of loss for the given period.
Volatility was left at 2.86%, however, over the last 30 days, the volatility rate increased by 3.73%, as shares sank -8.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +33.57% upper at present.
During the last 5 trading sessions, PCVX fell by -6.30%, which changed the moving average for the period of 200-days by +73.85% in comparison to the 20-day moving average, which settled at $112.81. In addition, Vaxcyte Inc saw 68.09% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PCVX starting from GUGGENHIME ANDREW, who sale 42,000 shares at the price of $115.39 back on Oct 18 ’24. After this action, GUGGENHIME ANDREW now owns 90,383 shares of Vaxcyte Inc, valued at $4,846,508 using the latest closing price.
GUGGENHIME ANDREW, the Officer of Vaxcyte Inc, proposed sale 42,000 shares at $115.88 during a trade that took place back on Oct 18 ’24, which means that GUGGENHIME ANDREW is holding shares at $4,866,960 based on the most recent closing price.
Stock Fundamentals for PCVX
Current profitability levels for the company are sitting at:
- -34.76 for the present operating margin
- 0.17 for the gross margin
The net margin for Vaxcyte Inc stands at -34.42. The total capital return value is set at -0.25. Equity return is now at value -29.08, with -27.70 for asset returns.
Based on Vaxcyte Inc (PCVX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -18.25. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -46.8.
Currently, EBITDA for the company is -464.88 million with net debt to EBITDA at 1.01. When we switch over and look at the enterprise to sales, we see a ratio of 855.91. The receivables turnover for the company is 0.81for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.88.
Conclusion
In a nutshell, Vaxcyte Inc (PCVX) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
